Used in the treatment of inflammatory skin diseases such as generalized pustular psoriasis (GPP), this antibody targets the IL-36 receptor to block the IL-36 signaling pathway, which plays a key role in driving inflammation. By inhibiting this pathway, it helps reduce the formation of pustules, skin redness, and systemic inflammation. It is particularly effective in patients with GPP flares, including those with genetic mutations linked to IL-36 pathway overactivation. Clinical development focuses on providing a targeted, biologic therapy for rare, autoinflammatory conditions with high unmet medical need.